NASDAQ:LRMR

Larimar Therapeutics (LRMR) Stock Forecast, Price & News

$4.36

-0.13 (-2.90%)

(As of 09/28/2023 ET)

Compare

Today's Range: $4.34
▼
$4.49
50-Day Range: $3.11
▼
$4.49
52-Week Range: $2.58
▼
$6.85

Volume: 107,185 shs
Average Volume: 129,770 shs
Market Capitalization: $188.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.83

Larimar Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 171.4% Upside
$11.83 Price Target
Short Interest: Healthy
1.39% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.81) to ($0.99) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

396th out of 969 stocks

Pharmaceutical Preparations Industry

171st out of 453 stocks

3.4

Analyst's Opinion

Consensus Rating
Larimar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.83, Larimar Therapeutics has a forecasted upside of 171.4% from its current price of $4.36.
Amount of Analyst Coverage
Larimar Therapeutics has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.39% of the outstanding shares of Larimar Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Larimar Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Larimar Therapeutics has recently decreased by 5.07%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Larimar Therapeutics does not currently pay a dividend.
Dividend Growth
Larimar Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LRMR.

3.3

News and Social Media Coverage

News Sentiment
Larimar Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Larimar Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
2 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Larimar Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Larimar Therapeutics is held by insiders.
Percentage Held by Institutions
91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Larimar Therapeutics are expected to decrease in the coming year, from ($0.81) to ($0.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Larimar Therapeutics is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Larimar Therapeutics is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Larimar Therapeutics has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Larimar Therapeutics (NASDAQ:LRMR) Stock

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.

LRMR Price History

30 days | 90 days | 365 days | Advanced Chart

LRMR Stock News Headlines

August 31, 2023 | finance.yahoo.com

Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference

August 15, 2023 | markets.businessinsider.com

Larimar Therapeutics (LRMR) Receives a Buy from JMP Securities

September 29, 2023 | Altimetry (Ad)

Surprising "Twist" Hands Biden Landslide Re-election?

This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.

August 11, 2023 | seekingalpha.com

Larimar Therapeutics GAAP EPS of -$0.34 misses by $0.14

August 11, 2023 | markets.businessinsider.com

JMP Securities Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)

August 11, 2023 | markets.businessinsider.com

LifeSci Capital Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

August 10, 2023 | finance.yahoo.com

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

August 7, 2023 | finance.yahoo.com

Larimar Therapeutics Insiders Placed Bullish Bets Worth US$1.2m

September 29, 2023 | Altimetry (Ad)

Surprising "Twist" Hands Biden Landslide Re-election?

This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.

July 28, 2023 | bizjournals.com

Lab Notes: Larimar Therapeutics is once again advancing its lead drug candidate following FDA delay

July 28, 2023 | seekingalpha.com

Larimar, Design higher as they benefit from Biogen deal for Reata

July 26, 2023 | markets.businessinsider.com

JMP Securities Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

July 25, 2023 | finance.yahoo.com

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

July 25, 2023 | finance.yahoo.com

These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say Analysts

July 19, 2023 | benzinga.com

Larimar Therapeutics Chief Medical Officer Awarded $583K Worth of Stock Options

July 17, 2023 | finance.yahoo.com

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

June 21, 2023 | seekingalpha.com

Larimar Therapeutics to join Russell 3000 Index

June 21, 2023 | finance.yahoo.com

Larimar Therapeutics Set to Join Russell 3000® Index

May 18, 2023 | msn.com

Guggenheim Maintains Larimar Therapeutics (LRMR) Buy Recommendation

May 18, 2023 | msn.com

Citigroup Maintains Larimar Therapeutics (LRMR) Neutral Recommendation

May 18, 2023 | markets.businessinsider.com

Where Larimar Therapeutics Stands With Analysts

May 17, 2023 | markets.businessinsider.com

Larimar's Ataxia Demonstrated Shows Better-Than-Expected Frataxin Increase, Analyst Says

May 16, 2023 | msn.com

JMP Securities Reiterates Larimar Therapeutics (LRMR) Market Outperform Recommendation

May 15, 2023 | markets.businessinsider.com

LifeSci Capital Sticks to Its Buy Rating for Larimar Therapeutics (LRMR)

May 15, 2023 | msn.com

Larimar Therapeutics Discloses Lower Dose Data Of Investigational Drug For Rare Neurodegenerative Disorder, Shares Plummet

May 15, 2023 | seekingalpha.com

Larimar falls 29% after Phase 2 data for lead asset and Q1 financials

May 15, 2023 | msn.com

Larimar Crashes Even after Positive Topline Data

See More Headlines

Receive LRMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LRMR Company Calendar

Last Earnings: 8/10/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LRMR
CUSIP: N/A
CIK: 1374690
Web: larimartx.com
Phone: (844) 511-9056
Fax: N/A
Employees: 26
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.83
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $4.50
Forecasted Upside/Downside: +171.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -29.96%
Return on Assets: -26.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.64
Quick Ratio: 14.64

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.56 per share
Price / Book: 1.70

Miscellaneous

Outstanding Shares: 43,280,000
Free Float: 41,417,000
Market Cap: $188.70 million
Optionable: Not Optionable
Beta: 0.50

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Carole S. Ben-Maimon M.D. (Age 64)
CEO, Pres & Director
Comp: $845.63k

Mr. Michael Celano CPA (Age 64)
Sec. & CFO
Comp: $562.62k

Mr. John Berman
VP of Fin. & Admin.

Ms. Jennifer Spokes Johansson
VP of Regulatory, Quality & Legal

Dr. Russell G. Clayton Sr. (Age 62)
D.O, Chief Medical Officer

Dr. Gopi Shankar M.B.A. (Age 52)
Ph.D., Chief Devel. Officer

Mr. Francis Michael Conway CPA
VP & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LRMR Stock - Frequently Asked Questions

Should I buy or sell Larimar Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LRMR shares.
View LRMR analyst ratings or view top-rated stocks.
What is Larimar Therapeutics' stock price forecast for 2023?: 4 equities research analysts have issued 1 year target prices for Larimar Therapeutics' stock. Their LRMR share price forecasts range from $4.50 to $17.00. On average, they expect the company's stock price to reach $11.83 in the next twelve months. This suggests a possible upside of 171.4% from the stock's current price.
View analysts price targets for LRMR or view top-rated stocks among Wall Street analysts.
How have LRMR shares performed in 2023?: Larimar Therapeutics' stock was trading at $4.13 at the beginning of the year. Since then, LRMR stock has increased by 5.6% and is now trading at $4.36.
View the best growth stocks for 2023 here.
When is Larimar Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our LRMR earnings forecast.
How were Larimar Therapeutics' earnings last quarter?: Larimar Therapeutics, Inc. (NASDAQ:LRMR) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.02.

What is Larimar Therapeutics' stock symbol?: Larimar Therapeutics trades on the NASDAQ under the ticker symbol "LRMR."
Who are Larimar Therapeutics' major shareholders?: Larimar Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include CHI Advisors LLC (7.89%), BlackRock Inc. (3.32%), Point72 Asset Management L.P. (1.94%), Geode Capital Management LLC (1.24%), State Street Corp (0.99%) and Dimensional Fund Advisors LP (0.74%). Insiders that own company stock include James E Flynn, Joseph Truitt, Michael Celano and Thomas Edward Hamilton.
View institutional ownership trends.
How do I buy shares of Larimar Therapeutics?: Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Larimar Therapeutics' stock price today?: One share of LRMR stock can currently be purchased for approximately $4.36.
How much money does Larimar Therapeutics make?: Larimar Therapeutics (NASDAQ:LRMR) has a market capitalization of $188.70 million. The company earns $-35,350,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.
How can I contact Larimar Therapeutics?: Larimar Therapeutics' mailing address is THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA, 19004. The official website for the company is larimartx.com. The company can be reached via phone at (844) 511-9056 or via email at investors@larimartx.com.

This page (NASDAQ:LRMR) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial